Company Focus
Baxter
Latest Baxter News
Pharmaceutical
Russia has faced with the shortage of oncology drug Uromitexan (mercapto ethane sulphonacid; mesna), for which last deliveries to the country were in the spring of 2023, reports The Pharma Letter’s local correspondent. 15 May 2024
Related News
Insights
Company Spotlight
A Canadian biotech company focussed on utilising lipid nanoparticle (LNP) for nucleic acid delivery.
Latest News & Features of interest to Baxter
Biotechnology
Positive results from the AMPLIFY Phase III trial have shown that adding AstraZeneca’s Calquence (acalabrutinib) to venetoclax led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukaemia (CLL). 9 December 2024
Pharmaceutical
Chinese biotech Abbisko Therapeutics has shared Phase II trial results for its oral CSF-1R inhibitor pimicotinib at the 66th ASH annual conference in San Diego. 9 December 2024
Biotechnology
Johnson & Johnson has unveiled positive early data for its multiple myeloma treatment Tecvayli (teclistamab) from two clinical studies focused on people with newly diagnosed multiple myeloma. 9 December 2024
Pharmaceutical
Sanofi has unveiled promising Phase III results for rilzabrutinib, its oral Bruton’s tyrosine kinase (BTK) inhibitor, at this year’s American Society of Hematology (ASH) meeting. 9 December 2024
Biotechnology
US biotech Regeneron Pharmaceuticals on Sunday announced positive updated Phase III data of an exploratory cohort from the ACCESS-1 trial investigating its first-in-class pozelimab and cemdisiran (poze-cemdi) combination treatment against ravulizumab, a standard-of-care complement factor 5 (C5) inhibitor, in patients with paroxysmal nocturnal hemoglobinuria (PNH). 9 December 2024
Pharmaceutical
Novartis today announced positive top-line results from APPULSE-PNH, a Phase IIIb study on the efficacy and safety of twice-daily oral monotherapy Fabhalta(iptacopan). 6 December 2024
Biotechnology
Pfizer (NYSE: PFE) emerged as a global hero during the COVID-19 pandemic, delivering critical medicines at unprecedented speed and saving millions of lives worldwide. 6 December 2024
Pharmaceutical
UK pharma major GSK has into an agreement with Chongqing Zhifei Biological Products (Zhifei) to revize the terms on which Zhifei will commercialize GSK’s shingles vaccine, Shingrix, in mainland China. 5 December 2024
Biotechnology
Refoxy Pharmaceuticals has raised 9.1 million euros ($10 million) in seed-extension financing led by Boehringer Ingelheim Venture Fund (BIVF), with support from Apollo Health Ventures and others. 4 December 2024
Pharmaceutical
Maze Therapeutics, a California-based biotech, has raised $115 million in a series D financing round co-led by Frazier Life Sciences and Deep Track Capital. 4 December 2024
Latest In Brief for Baxter
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Latest Relevant Ones To Watch News
Privately-held immunotherapy company Inmagene Biopharmaceuticals is taking over Ikena Oncology in a reverse merger deal, forming a new company, InmageneBio. 27 December 2024
19 December 2024
16 December 2024
3 December 2024
28 November 2024
26 November 2024
19 November 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze